1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMultidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) is sponsored by National Institutes of Health (NIH). Supports research to accelerate hepatitis B cure in individuals co-infected with HIV and HBV, focusing on mechanisms of persistence, pathogenesis, biomarkers, and non-invasive diagnostics.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) Agency: National Institutes of Health Assistance Listings: 93. 855 -- Allergy and Infectious Diseases Research Last Updated: June 27, 2025 View version history on Grants.
gov The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by soliciting applications to support Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV (PLWH) and Hepatitis B Virus (HBV).
This program will focus on: elucidating mechanisms of persistence and pathogenesis; discovering and developing clinically relevant biomarkers; discovering and/or validating host and/or new viral drug targets; and developing non-invasive diagnostics.
Each MRA-HBV award will support an observational cohort paired with a multi-disciplinary teams focused on research that leverages samples from existing clinical data and sample repositories from previous cohort studies.
Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Federally recognized Native American tribal governments Public and Indian housing authorities For-profit organizations other than small businesses Private institutions of higher education Public and state institutions of higher education Independent school districts Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Grantor contact information National Institute of Allergy and Infectious Disease (NIAID) No documents are currently available.
Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity :
According to the current listing, eligibility includes: Nonprofits, universities, state/local governments, and other research institutions. Confirm the full requirements in the official notice before applying.
Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article